7.3 Naloxone Access & Public Health Programs
Key Takeaways
- New York's statewide pharmacy naloxone standing order (Public Health Law §3309), effective August 15, 2022, lets any NY pharmacy dispense naloxone to an eligible recipient without an individual prescription.
- The Naloxone Co-payment Assistance Program (N-CAP) provides up to $40 in copay assistance for patients with prescription drug coverage, with no separate patient enrollment required.
- PHL §3331(5)(b), effective since July 22, 2016, limits an initial opioid prescription for acute pain to a 7-day supply, exempting cancer care, hospice/end-of-life care, immediate post-surgical treatment, and medical emergencies.
- The 7-day acute-pain limit does not apply to chronic pain management at all, because the rule's trigger is specifically an initial prescription for acute pain.
- A New York law effective January 1, 2026 requires qualifying health insurers — not pharmacies — to cover medically necessary epinephrine auto-injector and nasal-spray devices, capping patient out-of-pocket costs at $100 per year.
Overview
Area 2 of the NY MPJE tests pharmacist authority around harm reduction and controlled-substance access limits together. This section covers four distinct legal instruments: the naloxone standing order, the Naloxone Co-payment Assistance Program (N-CAP), the opioid initial-supply limit, and the newly effective epinephrine insurance-coverage law. They are easy to conflate on exam day because all four involve emergency medications, but each has a different legal mechanism and a different audience (pharmacies, patients, or insurers).
The Statewide Naloxone Standing Order — PHL §3309
New York's statewide pharmacy standing order for naloxone took effect August 15, 2022, issued under Public Health Law (PHL) §3309 (Article 33, Title 1 — Opioid Overdose Prevention). Under this standing order:
- Every pharmacy in New York State may dispense naloxone (an opioid antagonist) to an eligible recipient without an individual, named-patient prescription — the dispensing rests on a non-patient-specific order.
- Eligible opioid antagonist recipients include a person at risk of overdose, a family member, a friend, or an employee of a registered opioid overdose prevention program, reflecting the statute's broad public-health design across settings such as schools, libraries, bars, and retail establishments.
- Large chain pharmacies with 20 or more locations statewide must either obtain the standing order themselves or register as an opioid overdose prevention program (OOPP) — a structural requirement the MPJE can test as a which-pharmacy-must-additionally-register question.
- Distribution under the program is expected to include informational materials — and, consistent with the statute's harm-reduction framework, resources such as fentanyl test strips — covering how to recognize an overdose, when to call for emergency help, and the Good Samaritan liability protections available to a bystander who intervenes.
- Immunity: a person or entity acting reasonably and in good faith is protected from criminal, civil, and administrative liability for actions taken solely to prevent an overdose under §3309. This immunity covers both the bystander who administers naloxone and the pharmacist who dispenses it under the standing order.
Naloxone Co-payment Assistance Program (N-CAP)
N-CAP is a New York State Department of Health AIDS Institute pharmacy benefit that reduces the out-of-pocket cost of naloxone for New Yorkers who have prescription drug coverage:
- Covers naloxone dispensed over-the-counter, or under any valid prescription or standing order.
- Available to anyone with commercial prescription coverage — no individual enrollment in N-CAP is required of the patient.
- Provides co-payment assistance of up to $40 at participating pharmacies.
- Naloxone through N-CAP-participating pharmacies is available at more than 2,600 pharmacy locations statewide.
For the exam, remember that N-CAP is a cost-assistance program layered on top of dispensing authority — §3309 is what lets the pharmacist dispense without an individual prescription; N-CAP is what keeps the copay low once dispensed.
Opioid Initial-Supply Limit — PHL §3331(5)(b)
Since July 22, 2016, PHL §3331(5)(b) has limited a practitioner's initial opioid prescription for acute pain:
- A practitioner may not prescribe more than a 7-day supply of a Schedule II, III, or IV opioid on the initial consultation or treatment of a patient for acute pain.
- Acute pain is defined as pain — from disease, accidental or intentional trauma, or another cause — that the practitioner reasonably expects to last only a short period of time.
- On subsequent consultations for the same pain, the practitioner may issue an appropriate renewal, refill, or new prescription without being bound again by the 7-day cap.
- The limit does not apply to: treatment of cancer; hospice or other end-of-life care; post-surgical treatment immediately following a surgical procedure; or a medical emergency.
- The rule targets acute pain by definition — a practitioner managing a patient's chronic pain is not operating inside the acute-pain trigger at all, so the 7-day cap is not the applicable rule for that encounter in the first place.
Quick-Reference Table
| Rule element | Detail |
|---|---|
| Statute | PHL §3331(5)(b) |
| Effective | July 22, 2016 |
| Cap | 7-day supply, Schedule II–IV opioids |
| Trigger | Initial Rx for acute pain |
| Exemptions | Cancer care; hospice/end-of-life care; immediate post-surgical treatment; medical emergency |
| Outside the rule's scope entirely | Chronic pain management |
A pharmacist who receives an initial acute-pain opioid prescription written for a 14-day supply, with no exemption noted, should treat it as facially non-compliant and contact the prescriber before dispensing.
Epinephrine Auto-Injector Coverage Law (Effective January 1, 2026)
New York enacted an insurance-coverage mandate for epinephrine devices, most recently amended by S760/A2443 (Chapter 81), building on 2024's L.2024 c.553, effective January 1, 2026:
- Health insurers issuing individual or group policies with major medical/comprehensive coverage and prescription drug coverage must cover medically necessary epinephrine auto-injector devices for the emergency treatment of life-threatening allergic reactions.
- Patient out-of-pocket cost-sharing is capped at $100 per year.
- A companion law (S7807A/A5392B) expanded the covered-device definition to include epinephrine nasal spray products, not just auto-injectors, so any FDA-approved epinephrine delivery product can qualify for coverage.
- Important distinction for the exam: this is an insurance-coverage and cost-sharing mandate on health plans, not a pharmacist-dispensing-authority statute. It does not create a naloxone-style standing order letting pharmacists dispense epinephrine without a prescription, and it does not impose a stocking mandate on pharmacies. Do not confuse it with PHL §3309.
Scenario Walkthrough
A patient without insurance asks a pharmacist for naloxone after a family member's near-fatal overdose. The pharmacist may dispense it under the §3309 standing order without an individual prescription, and if the patient does have prescription coverage, the copay may be reduced through N-CAP. The same day, a different patient's new prescriber writes an initial 10-day oxycodone prescription for acute post-dental-extraction pain with no post-surgical or emergency notation. The pharmacist should recognize the §3331(5)(b) 7-day cap issue and verify with the prescriber before filling more than a 7-day supply, unless a recognized exemption applies.
Under Public Health Law §3309, which pharmacies must additionally either obtain the naloxone standing order or register as an opioid overdose prevention program?
A patient with commercial prescription drug coverage requests naloxone at a participating New York pharmacy. Which statement about the Naloxone Co-payment Assistance Program (N-CAP) is correct?
A prescriber writes an initial opioid prescription for a 10-day supply for a patient recovering from major abdominal surgery performed two days earlier. Under PHL §3331(5)(b), is this compliant?
How should a New York pharmacist correctly characterize the epinephrine auto-injector law effective January 1, 2026?
A patient has been receiving opioid therapy for documented chronic low back pain for the past year, and her prescriber issues a renewal prescription for a 30-day supply. Does PHL §3331(5)(b)'s 7-day rule apply to this prescription?